Atherosclerosis regression and TP receptor inhibition: Effect of S18886 on plaque size and composition - A magnetic resonance imaging study

European Heart Journal

Volumn 26, Issue 15, 2005, Pages 1557-1561

  Viles Gonzalez, Juan F ^a   Fuster, Valentin ^a   Corti, Roberto ^b   Valdiviezo, Carolina ^a   Hutter, Randolph ^a   Corda, Stefano ^c   Anand, Sunil X ^a   Badimon, Juan J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c IRIS Institut de Recherches Internationales Servier   (France)

Author keywords

Antiplatelets; Atherosclerosis; Magnetic resonance imaging; MRI; Platelets; Thromboxane A2; Thromboxane receptor; TP receptor

Indexed keywords

ALPHA ACTIN; CASPASE 3; ENDOTHELIN 1; INTERSTITIAL COLLAGENASE; S 18886; THROMBOXANE A2 RECEPTOR BLOCKING AGENT;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; APOPTOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DRUG EFFECT; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RABBIT; RANDOMIZATION; RECEPTOR BLOCKING; REMISSION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; ARTERIOSCLEROSIS; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NAPHTHALENES; PROPIONIC ACIDS; RABBITS; RANDOM ALLOCATION; RECEPTORS, THROMBOXANE;

EID: 25444465119     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi175     Document Type: Article

References (33)

1. Kobayashi T, Tahara Y, Matsumoto M et al. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004;114:784-794.
2. Capone ML, Tacconelli S, Sciulli MG et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004;109:1468-1471.
3. Cheng Y, Austin SC, Rocca B et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002;296:539-541.
4. Trip MD, Cats VM, van Capelle FJ et al. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990;322:1549-1554.
5. Huo Y, Schober A, Forlow SB et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003;9:61-67.
6. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002;8:1227-1234.
7. Broijersen A, Hamsten A, Eriksson M et al. Platelet activity in vivo in hyperlipoproteinemia-importance of combined hyperlipidemia. Thromb Haemost 1998;79:268-275.
8. Broijersen A, Karpe F, Hamsten A et al. Alimentary lipemia enhances the membrane expression of platelet P-selectin without affecting other markers of platelet activation. Atherosclerosis 1998;137:107-113.
9. van Zanten GH, de Graaf S, Slootweg PJ et al. Increased platelet deposition on atherosclerotic coronary arteries. J Clin Invest 1994;93:615-632.
10. Viles-Gonzalez JF, Fuster V. Badimon J. Platelets and the vulnerable plaque. In: Waxman S, Serruys P, eds. Handbook of the Vulnerable Plaque. London, UK: Martin Dunitz; 2004.
11. Sarma J, Laan CA, Alam S et al. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002;105:2166-2171.
12. da Costa Martins P, van den Berk N, Ulfman LH et al. Platelet-monocyte complexes support monocyte adhesion to endothelium by enhancing secondary tethering and cluster formation. Arterioscler Thromb Vasc Biol 2004;24:193-199.
13. Osende JI, Shimbo D, Fuster V et al. Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist. J Thromb Haemost 2004;2:492-498.
14. Cayatte AJ, Du Y, Oliver-Krasinski J et al. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 2000;20:1724-1728.
15. Belhassen L, Pelle G, Dubois-Rande JL et al. Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 2003;41:1198-1204.
16. Helft G, Worthley SG, Fuster V et al. Progression and regression of atherosclerotic lesions: monitoring with serial noninvasive magnetic resonance imaging. Circulation 2002;105:993-998.
17. Skinner MP, Yuan C, Mitsumori L et al. Serial magnetic resonance imaging of experimental atherosclerosis detects lesion fine structure, progression and complications in vivo. Nat Med 1995;1:69-73.
18. McConnell MV, Aikawa M, Maier SE et al. MRI of rabbit atherosclerosis in response to dietary cholesterol lowering. Arterioscler Thromb Vasc Biol 1999;19:1956-1959.
19. Corti R, Osende JI, Fallon JT et al. The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging. J Am Coll Cardiol 2004;43:464-473.
20. Badimon L, Turitto V, Rosemark JA et al. Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene. J Lab Clin Med 1987;110:706-718.
21. Kearney D, Byrne A, Crean P et al. Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor. J Am Coll Cardiol 2004;43:526-531.
22. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
23. Cipollone F, Rocca B, Patrono C. Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 2004;24:246-255.
24. Topol EJ, Falk GW. A coxib a day won't keep the doctor away. Lancet 2004;364:639-640.
25. Chenevard R, Hurlimann D, Bechir M et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003;107:405-409.
26. Cimetiere B, Dubuffet T, Muller O et al. Synthesis and biological evaluation of new tetrahydronaphthalene derivatives as thromboxane receptor antagonists. Bioorg Med Chem Lett 1998;8:1375-1380.
27. Ishizuka T, Matsumura K, Matsui T et al. Ramatroban, a thromboxane A2 receptor antagonist, prevents macrophage accumulation and neointimal formation after balloon arterial injury in cholesterol-fed rabbits. J Cardiovasc Pharmacol 2003;41:571-578.
28. Ishizuka T, Matsui T, Kurita A. Ramatroban, a TP receptor antagonist, improves vascular responses to acetylcholine in hypercholesterolemic rabbits in vivo. Eur J Pharmacol 2003;468:27-35.
29. Neri Serneri GG, Coccheri S, Marubini E et al. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 2004;6:1845-1852.
30. Nassar T, Sachais BS, Akkawi S et al. Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J Biol Chem 2003;278:6187-6193.
31. Sachais BS, Kuo A, Nassar T et al. Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic machinery, resulting in retention of low-density lipoprotein on the cell surface. Blood 2002;99:3613-3622.
32. Hutter R, Valdiviezo C, Sauter BV et al. Caspase-3 and tissue factor expression in lipid-rich plaque macrophages: evidence for apoptosis as link between inflammation and atherothrombosis. Circulation 2004;109:2001-2008.
33. Kleiman NS. Platelets, the cardiologist, and coronary artery disease: moving beyond aggregation. J Am Coll Cardiol 2004;43:1989-1991.